Preservation of sexual function with Optilume—a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia
Rattachement africain : us, ca. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: The Optilume benign prostatic hyperplasia (BPH) catheter system is a novel minimally invasive paclitaxel-coated dilation system that has demonstrated substantial and durable results in urinary flow and symptoms. AIM: We now assess the impact of Optilume BPH procedure on sexual function. METHODS: Prior published results have described the methods of data collection during the PINNACLE study, which demonstrated durable improvement in urinary symptoms. Follow-up assessments for the current study included IIEF-EF and Male Sexual Health Questionnaire for Ejaculatory Dysfunction (MSHQ-EjD). Semen quality was also examined. OUTCOMES: IIEF-EF and MSHQ-EjD scores in the Optilume BPH group were not different from the sham group at 3 months, 6 months, or 12 months. RESULTS: A total of 148 men were randomized to receive the procedure (100) or a sham surgical procedure (48). Subjects in both groups had similar rates of erectile dysfunction (ED) previously diagnosed at baseline (56% vs 54.2%, P = .83) and those men who were sexually active. IIEF-EF and MSHQ-EjD scores in the Optilume BPH group were not different from the sham group at 3, 6, or 12 months. Change in IIEF-EF scores remained consistent across all levels of baseline ED severity after Optilume BPH procedure. No clear trend was seen after treatment with Optilume BPH for semen volume, sperm motility, progressive motility, or sperm morphology. CLINICAL IMPLICATIONS: The Optilume BPH catheter system provides patients with a durable improvement in lower urinary tract symptoms while preserving sexual function. STRENGTHS AND LIMITATIONS: This study uses validated questionnaires to assess patients' sexual function at baseline and regularly for 1 year after the procedure. Given exclusion criteria regarding patient age and prostate size, the results may not be applicable to all BPH phenotypes. CONCLUSION: Optilume appears to provide clinical benefit with a high degree of patient satisfaction and minimal impact on sexual function.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Preservation of sexual function with Optilume—a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia
- Date Crossref
- 19/01/2025
- Éditeur
- Oxford University Press (OUP)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Louisiana State University Health Sciences Center Shreveport pays non établi dans la noticeÉtablissement de santé
-
New Jersey Urology pays non établi dans la noticeÉtablissement de santé
-
University of Toronto pays non établi dans la noticeUniversité ou école supérieure
-
Arkansas Department of Agriculture pays non établi dans la noticeOrganisme public
-
Florida Urology Associates pays non établi dans la noticeÉtablissement de santé
-
Carolina Urologic Research Center pays non établi dans la noticeStructure de recherche
-
Urology San Antonio pays non établi dans la noticeÉtablissement de santé
-
Manhattan Scientifics (United States) pays non établi dans la noticeEntreprise
-
Manhattan Medical Research pays non établi dans la noticeStructure de recherche
-
Cornell University pays non établi dans la noticeUniversité ou école supérieure
-
Mount Sinai Health System pays non établi dans la noticeÉtablissement de santé
-
The Center for Men’s Health Stritch School of Medicine pays non établi dans la noticeUniversité ou école supérieure
Louisiana State University Health Sciences Center Shreveport, New Jersey Urology et University of Toronto, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.